Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250230 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1 | |
| Iodide SCHEMBL27752821 | 0.78 | — | — | |
| SCHEMBL30140471 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRTDP1 | |
| SCHEMBL28715541 | 0.75 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1 | |
| SCHEMBL9347120 | 0.74 | ALDH1A1 (0.40) | ALDH1A1TSHRTDP1 | |
| SCHEMBL8568302 | 0.74 | ALDH1A1 (0.40) | ALDH1A1TSHRTDP1 | |
| SCHEMBL8572482 | 0.74 | ALDH1A1 (0.40) | ALDH1A1TSHRTDP1 | |
| SCHEMBL8568515 | 0.74 | ALDH1A1 (0.40) | ALDH1A1TSHRTDP1 | |
| SCHEMBL9343720 | 0.74 | ALDH1A1 (0.40) | ALDH1A1TSHRTDP1 | |
| SCHEMBL7582512 | 0.71 | ALDH1A1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362022-B1 | METHOD FOR PRODUCING ORTHOCARBONIC ACID TRIALKYL ESTERS | BASF AG (DE) | 2007-11-28 | — | — | EP | claimed |
| US-7192512-B2 | Method for producing orthocarbonic acid trialkyl esters | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-20 | — | — | US | claimed |
| CN-1249004-C | Method for producing orthocarbonic acid trialkyl esters | BASF AG (DE) | 2006-04-05 | — | — | CN | claimed |
| CN-1454198-A | Method for producing orthocarbonic acid trialkyl esters | BASF AG (DE) | 2003-11-05 | — | — | CN | claimed |
| US-20030183534-A1 | Method for producing orthocarbonic acid trialkyl esters | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-02 | — | — | US | claimed |
| EP-4651903-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250144589-A1 | Method for Producing Microcapsules | SYMRISE AG (DE) | 2025-05-08 | — | — | US | disclosed |
| EP-4472763-A1 | METHOD FOR PRODUCING MICROCAPSULES | Symrise AG (DE) | 2024-12-11 | — | — | EP | disclosed |
| US-20240335544-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024155748-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| EP-4370156-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023148253-A1 | METHOD FOR PRODUCING MICROCAPSULES | SYMRISE AG (DE) | 2023-08-10 | — | — | WO | disclosed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | disclosed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | disclosed |
| CN-103119016-A | Method for preparing ingenol-3-angelate | LEO PHARMA AS | 2013-05-22 | — | — | CN | disclosed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
| CN-1249004-C | Method for producing orthocarbonic acid trialkyl esters | BASF AG (DE) | 2006-04-05 | — | — | CN | disclosed |
| WO-2003057663-A1 | PREPARATION OF ALPHA-DIIMINES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030130514-A1 | Preparation of alpha-diimines | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-07-10 | — | — | US | disclosed |
| US-4960954-A | ELIMINATING ALCOHOL FROM ACETAL OR KETAL USING PHOSPHATE OR ZEOLITE CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335544-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | M6PR, IGF2R, ASGR1 | ALDH1A1 4221/4885TSHR 377/4885TDP1 3471/4885 |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | ALDH1A1 1005/4885TSHR 2588/4885TDP1 4383/4885 |
| US-20030130514-A1 | Preparation of alpha-diimines | ADRA1A, KCNMA1, TUBA1A | ALDH1A1 119/4885TSHR 4488/4885TDP1 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.